As of the latest Form 4 filed Jun 3, 2026.
What Baxter International Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Newest filing first — the 26 most recent filings for BAX.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-03 | 2026-06-02 | Wallace Steven P. President, Adv. Surgery | FTax | −153.00 | $18.68 | $2.86K | No | Form 4 ↗ |
| 2026-06-03 | 2026-06-02 | Teaff James President, CCS | FTax | −321.00 | $18.68 | $6.00K | No | Form 4 ↗ |
| 2026-06-03 | 2026-06-01 | Zielinski Anita A SVP, Interim CFO, CAO & Cntrlr | AAward | +13.4K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-07 | 2026-05-05 | Wilkes David S. Director | AAward | +12.8K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-07 | 2026-05-05 | Wendell Amy McBride Director | AAward | +12.8K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-07 | 2026-05-05 | SCHLICHTING NANCY M Director | AAward | +12.8K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-07 | 2026-05-05 | MORRISON PATRICIA Director | AAward | +12.8K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-07 | 2026-05-05 | Shafer David Brent Director | AAward | +12.8K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-07 | 2026-05-05 | McDonnell Michael R. Director | AAward | +12.8K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-07 | 2026-05-05 | Craig Jeffrey A Director | AAward | +12.8K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-07 | 2026-05-05 | Ampofo William A. II Director | AAward | +12.8K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-10 | 2026-03-06 | Zielinski Anita A SVP, CAO and Controller | FTax | −1.93K | $17.69 | $34.2K | No | Form 4 ↗ |
| 2026-03-10 | 2026-03-06 | Soriano Maria Cecilia Group Pres., ITT & Pharma. | FTax | −2.85K | $17.69 | $50.4K | No | Form 4 ↗ |
| 2026-03-10 | 2026-03-06 | Rosenbloom David S. EVP and General Counsel | FTax | −6.62K | $17.69 | $117K | No | Form 4 ↗ |
| 2026-03-10 | 2026-03-06 | Rasul Reazur EVP,Group Pres,Healthcare | FTax | −12.7K | $17.69 | $224K | No | Form 4 ↗ |
| 2026-03-10 | 2026-03-06 | Grade Joel T. EVP and CFO | FTax | −8.15K | $17.69 | $144K | No | Form 4 ↗ |
| 2026-03-03 | 2026-03-02 | Rasul Reazur EVP,Group Pres,Healthcare | FTax | −1.61K | $19.69 | $31.8K | No | Form 4 ↗ |
| 2026-03-03 | 2026-03-02 | Soriano Maria Cecilia Group Pres., ITT & Pharma. | FTax | −1.85K | $19.69 | $36.5K | No | Form 4 ↗ |
| 2026-03-03 | 2026-03-02 | Rosenbloom David S. EVP and General Counsel | FTax | −1.34K | $19.69 | $26.3K | No | Form 4 ↗ |
| 2026-03-03 | 2026-02-27 | Hider Andrew P. President and CEO | AAward | +202K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-03 | 2026-02-27 | Carlisle Cynthia Executive Vice President, CHRO | AAward | +11.9K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-03 | 2026-02-27 | Carlisle Cynthia, Executive Vice President, CHRO | AAward | +17.8K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-03 | 2026-02-27 | Soriano Maria Cecilia Group Pres., ITT & Pharma. | AAward | +23.7K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-03 | 2026-02-27 | Rosenbloom David S. EVP and General Counsel | AAward | +26.7K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-03 | 2026-02-27 | Grade Joel T. EVP and CFO | AAward | +42.7K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-03 | 2026-02-27 | Zielinski Anita A SVP, CAO and Controller | AAward | +30.9K | $0.00 | $0.00 | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also BAX’s full analysis or the market-wide insider trading feed. The tabs above jump to BAX’s other SEC data.
Source: SEC Form 4 filings for BAX, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.